Evaluation of membrane type 1 metalloproteinase (MT1-MMP/MMP14) expression as a prognostic biomarker in patients with solid tumours screened for a Phase I/II trial
Name:
PetersN.pdf
Size:
67.33Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Peters, NiamhMorley, H
Khalique, S.
Scalzo, S.
Patel, R.
Gunaydin, U.
Funingana, G.
Evans, J.
Papadatos-Pastos, D.
Banjeri, U.
Basu, B.
Niewiarowski, A.
Symeonides, S.
Kelly, F.
Sawretse, L.
Bacon, C.
Robinson, M.
Gelb, T.
Blakemore, S.
Cook, Natalie
Affiliation
The Christie NHS Foundation Trust, Experimental Cancer Medicine, ManchesterIssue Date
2022
Metadata
Show full item recordCitation
Peters N, Morley H, Khalique S, Scalzo S, Patel R, Gunaydin U, et al. Evaluation of membrane type 1 metalloproteinase (MT1-MMP/MMP14) expression as a prognostic biomarker in patients with solid tumours screened for a Phase I/II trial. European Journal of Cancer. 2022 Oct;174:S117-S8. PubMed PMID: WOS:000876973400305.Journal
European Journal of CancerDOI
10.1016/S0959-8049(22)01114-5Additional Links
https://dx.doi.org/10.1016/S0959-8049(22)01114-5Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(22)01114-5